Gallbladder cancer – no improvement in survival over time in a Swedish population
Gallbladder cancer (GBC) has an extremely poor outcome. The aim of this study was to examine trends in GBC incidence, treatment and overall survival in a complete population of affected persons in a well-defined region in Sweden in 2000-2014. Altogether 546 individuals with GBC were identified at Sw...
Saved in:
Published in | Acta oncologica Vol. 57; no. 11; pp. 1482 - 1489 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
England
02.11.2018
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Gallbladder cancer (GBC) has an extremely poor outcome. The aim of this study was to examine trends in GBC incidence, treatment and overall survival in a complete population of affected persons in a well-defined region in Sweden in 2000-2014.
Altogether 546 individuals with GBC were identified at Sweden's Regional Cancer Centre West. Subjects were grouped into three 5-year periods (Period A: 2000-2004, Period B: 2005-2009 and Period C: 2010-2014) and the survival, diagnosis, staging, grading and treatment for each period were investigated. Patients dead at date of diagnosis (n = 39) and patients with not invasive cancer (n = 25) were not included in the analysis.
The incidence was unchanged over the study period. The survival curves for the time periods were not significantly separated. Median survival was 4.7 months in Period A, 4.8 months in Period B and 6.1 months in Period C. Stage migration to more M1 in Periods B and C occurred and survival was improved for these cohorts. More individuals were diagnosed using only diagnostic imaging (p = .02). There were 177 curatively aiming operative procedures carried out on 482 persons (37%). The survival after surgery for the three periods improved over time (p = .02). Individuals who underwent a liver bed resection after a cholecystectomy had better survival than individuals who had cholecystectomy combined with liver resection. More persons were treated with chemotherapy, but no significant impact was found on survival in the total GBC population.
Although there were signs of improved diagnosis of GBC, the survival rate did not improve over time. There was a significant stage migration to more M1 in Periods B and C. Therapeutics able to downsize a cancer and increase the effectiveness of surgery with curative intent are warranted. |
---|---|
AbstractList | Gallbladder cancer (GBC) has an extremely poor outcome. The aim of this study was to examine trends in GBC incidence, treatment and overall survival in a complete population of affected persons in a well-defined region in Sweden in 2000-2014.BACKGROUNDGallbladder cancer (GBC) has an extremely poor outcome. The aim of this study was to examine trends in GBC incidence, treatment and overall survival in a complete population of affected persons in a well-defined region in Sweden in 2000-2014.Altogether 546 individuals with GBC were identified at Sweden's Regional Cancer Centre West. Subjects were grouped into three 5-year periods (Period A: 2000-2004, Period B: 2005-2009 and Period C: 2010-2014) and the survival, diagnosis, staging, grading and treatment for each period were investigated. Patients dead at date of diagnosis (n = 39) and patients with not invasive cancer (n = 25) were not included in the analysis.MATERIAL AND METHODSAltogether 546 individuals with GBC were identified at Sweden's Regional Cancer Centre West. Subjects were grouped into three 5-year periods (Period A: 2000-2004, Period B: 2005-2009 and Period C: 2010-2014) and the survival, diagnosis, staging, grading and treatment for each period were investigated. Patients dead at date of diagnosis (n = 39) and patients with not invasive cancer (n = 25) were not included in the analysis.The incidence was unchanged over the study period. The survival curves for the time periods were not significantly separated. Median survival was 4.7 months in Period A, 4.8 months in Period B and 6.1 months in Period C. Stage migration to more M1 in Periods B and C occurred and survival was improved for these cohorts. More individuals were diagnosed using only diagnostic imaging (p = .02). There were 177 curatively aiming operative procedures carried out on 482 persons (37%). The survival after surgery for the three periods improved over time (p = .02). Individuals who underwent a liver bed resection after a cholecystectomy had better survival than individuals who had cholecystectomy combined with liver resection. More persons were treated with chemotherapy, but no significant impact was found on survival in the total GBC population.RESULTSThe incidence was unchanged over the study period. The survival curves for the time periods were not significantly separated. Median survival was 4.7 months in Period A, 4.8 months in Period B and 6.1 months in Period C. Stage migration to more M1 in Periods B and C occurred and survival was improved for these cohorts. More individuals were diagnosed using only diagnostic imaging (p = .02). There were 177 curatively aiming operative procedures carried out on 482 persons (37%). The survival after surgery for the three periods improved over time (p = .02). Individuals who underwent a liver bed resection after a cholecystectomy had better survival than individuals who had cholecystectomy combined with liver resection. More persons were treated with chemotherapy, but no significant impact was found on survival in the total GBC population.Although there were signs of improved diagnosis of GBC, the survival rate did not improve over time. There was a significant stage migration to more M1 in Periods B and C. Therapeutics able to downsize a cancer and increase the effectiveness of surgery with curative intent are warranted.CONCLUSIONSAlthough there were signs of improved diagnosis of GBC, the survival rate did not improve over time. There was a significant stage migration to more M1 in Periods B and C. Therapeutics able to downsize a cancer and increase the effectiveness of surgery with curative intent are warranted. Gallbladder cancer (GBC) has an extremely poor outcome. The aim of this study was to examine trends in GBC incidence, treatment and overall survival in a complete population of affected persons in a well-defined region in Sweden in 2000-2014. Altogether 546 individuals with GBC were identified at Sweden's Regional Cancer Centre West. Subjects were grouped into three 5-year periods (Period A: 2000-2004, Period B: 2005-2009 and Period C: 2010-2014) and the survival, diagnosis, staging, grading and treatment for each period were investigated. Patients dead at date of diagnosis (n = 39) and patients with not invasive cancer (n = 25) were not included in the analysis. The incidence was unchanged over the study period. The survival curves for the time periods were not significantly separated. Median survival was 4.7 months in Period A, 4.8 months in Period B and 6.1 months in Period C. Stage migration to more M1 in Periods B and C occurred and survival was improved for these cohorts. More individuals were diagnosed using only diagnostic imaging (p = .02). There were 177 curatively aiming operative procedures carried out on 482 persons (37%). The survival after surgery for the three periods improved over time (p = .02). Individuals who underwent a liver bed resection after a cholecystectomy had better survival than individuals who had cholecystectomy combined with liver resection. More persons were treated with chemotherapy, but no significant impact was found on survival in the total GBC population. Although there were signs of improved diagnosis of GBC, the survival rate did not improve over time. There was a significant stage migration to more M1 in Periods B and C. Therapeutics able to downsize a cancer and increase the effectiveness of surgery with curative intent are warranted. Background: Gallbladder cancer (GBC) has an extremely poor outcome. The aim of this study was to examine trends in GBC incidence, treatment and overall survival in a complete population of affected persons in a well-defined region in Sweden in 2000-2014. Material and methods: Altogether 546 individuals with GBC were identified at Sweden's Regional Cancer Centre West. Subjects were grouped into three 5-year periods (Period A: 2000-2004, Period B: 2005-2009 and Period C: 2010-2014) and the survival, diagnosis, staging, grading and treatment for each period were investigated. Patients dead at date of diagnosis (n = 39) and patients with not invasive cancer (n = 25) were not included in the analysis. Results: The incidence was unchanged over the study period. The survival curves for the time periods were not significantly separated. Median survival was 4.7 months in Period A, 4.8 months in Period B and 6.1 months in Period C. Stage migration to more M1 in Periods B and C occurred and survival was improved for these cohorts. More individuals were diagnosed using only diagnostic imaging (p = .02). There were 177 curatively aiming operative procedures carried out on 482 persons (37%). The survival after surgery for the three periods improved over time (p = .02). Individuals who underwent a liver bed resection after a cholecystectomy had better survival than individuals who had cholecystectomy combined with liver resection. More persons were treated with chemotherapy, but no significant impact was found on survival in the total GBC population. Conclusions: Although there were signs of improved diagnosis of GBC, the survival rate did not improve over time. There was a significant stage migration to more M1 in Periods B and C. Therapeutics able to downsize a cancer and increase the effectiveness of surgery with curative intent are warranted. |
Author | Lindnér, Per Hafström, Lo Holmberg, Erik |
Author_xml | – sequence: 1 givenname: Per surname: Lindnér fullname: Lindnér, Per organization: Transplant Institute, Institute of Clinical Sciences Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden – sequence: 2 givenname: Erik orcidid: 0000-0001-5107-4550 surname: Holmberg fullname: Holmberg, Erik organization: Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden – sequence: 3 givenname: Lo surname: Hafström fullname: Hafström, Lo organization: Transplant Institute, Institute of Clinical Sciences Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29932778$$D View this record in MEDLINE/PubMed https://gup.ub.gu.se/publication/274609$$DView record from Swedish Publication Index |
BookMark | eNp9kc1KxDAUhYMoOo4-gpKlm45JmjYprkT8gwEXKrgLaXqrkfTHpJ3Bne_gG_okts6MCxeuLhy-cy73nn20XTc1IHREyYwSSU4Jk5zK9GnGCJUzyoWkjG-hCU0TGjGWPm2jychEI7SH9kN4JYSwWCS7aI9lWcyEkBN0f62dy50uCvDY6NoM4-vjE9cNtlXrmwVUUHfY1jj0fmEX2uFB87izFYyqxvdLKGx4wW3T9k53tqkP0E6pXYDD9Zyix6vLh4ubaH53fXtxPo9MnPEuEiIDRuNcClGUjJrCgOGM5aLItUwNFdRwgCJNWZloKhLDS5EQLgWUstSaxVMUrXLDEto-V623lfbvqtFWPfetGqTnXgVQTPCUZAN_suKHu956CJ2qbDDgnK6h6YNiJJEJkZTTAT1eo31eQfEbvXncAJytAOObEDyUytju5_rOa-sUJWqsSW1qUmNNal3T4E7-uDcL_vd9A0sDlu0 |
CitedBy_id | crossref_primary_10_1080_00365521_2021_1915373 crossref_primary_10_1089_cbr_2021_0016 crossref_primary_10_1016_j_heliyon_2025_e42853 crossref_primary_10_1007_s12032_022_01874_x crossref_primary_10_1002_ijc_33980 crossref_primary_10_1136_bmjopen_2020_038634 crossref_primary_10_1186_s12885_025_13711_1 crossref_primary_10_1177_14574969241263539 crossref_primary_10_3389_fonc_2022_889334 crossref_primary_10_1007_s12029_020_00397_w crossref_primary_10_1055_s_0040_1721180 crossref_primary_10_1097_MD_0000000000034163 crossref_primary_10_2147_JIR_S399586 crossref_primary_10_25259_IJMIO_10_2021 |
Cites_doi | 10.1093/oxfordjournals.annonc.a010676 10.1046/j.1440-1746.2001.02520.x 10.1056/NEJMoa0908721 10.1111/hpb.12444 10.1080/00365521.2017.1284895 10.1634/theoncologist.2009-0302 10.1007/s12094-012-0988-7 10.1186/s12885-015-1617-y 10.1007/s11605-010-1335-3 10.1002/jmri.24537 10.1002/cncr.20160 10.1186/1470-7330-14-14 10.1155/2015/967472 |
ContentType | Journal Article |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 ADTPV AOWAS F1U |
DOI | 10.1080/0284186X.2018.1478124 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic SwePub SwePub Articles SWEPUB Göteborgs universitet |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1651-226X |
EndPage | 1489 |
ExternalDocumentID | oai_gup_ub_gu_se_274609 29932778 10_1080_0284186X_2018_1478124 |
Genre | Journal Article |
GeographicLocations | Sweden |
GeographicLocations_xml | – name: Sweden |
GroupedDBID | --- 00X 03L 23M 2WC 36B 4.4 5GY 5RE 6J9 AAFWJ AALUX AAMIU AAPUL AAWTL AAYXX ABDBF ABEIZ ABJNI ABLIJ ABLJU ABLKL ABNNA ABUPF ABXYU ACGEJ ACGFO ACGFS ACIEZ ACUHS ADBBV ADCVX ADRBQ ADXPE AECIN AEGXH AENEX AEOZL AFKVX AFPKN AGDLA AGFJD AGYJP AIAGR AIJEM AJWEG AKBVH ALMA_UNASSIGNED_HOLDINGS ALQZU BABNJ BAWUL BLEHA BOHLJ CCCUG CITATION COF CS3 DKSSO EAP EBB EBC EBD EBS EBX EJD EMB EMK EMOBN EPL ESX F5P GROUPED_DOAJ H13 HZ~ KRBQP KSSTO KWAYT KYCEM L7B M4Z O9- OK1 P2P PGMZT SV3 TBQAZ TDBHL TERGH TFDNU TFL TFW TUS UEQFS V1S WH7 ~1N .55 .GJ 0BK 3O- 53G 5VS AALIY AAPXX ABFIM ABWCV ABZEW ACCJX ACENM ACKZS ADFOM ADFZZ AEIIZ AEXWM AFFNX AFLEI AJVHN ALYBC AWYRJ BRMBE CAG CGR CUY CVF CYYVM CZDIS DIK DRXRE DWTOO ECM EIF GX1 JENTW LJTGL M44 NPM NUSFT OVD RPM TEORI X7M ZGI ZXP 7X8 ADTPV AOWAS F1U |
ID | FETCH-LOGICAL-c394t-779e213b877df21cdcec422b7dba86c171c4eed662f5a175c4f750487ef8faa23 |
ISSN | 0284-186X 1651-226X |
IngestDate | Thu Aug 21 07:14:41 EDT 2025 Fri Jul 11 11:00:01 EDT 2025 Thu Jan 02 23:01:24 EST 2025 Tue Jul 01 04:59:46 EDT 2025 Thu Apr 24 23:12:03 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 11 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c394t-779e213b877df21cdcec422b7dba86c171c4eed662f5a175c4f750487ef8faa23 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0001-5107-4550 |
OpenAccessLink | https://www.tandfonline.com/doi/pdf/10.1080/0284186X.2018.1478124?needAccess=true |
PMID | 29932778 |
PQID | 2058508141 |
PQPubID | 23479 |
PageCount | 8 |
ParticipantIDs | swepub_primary_oai_gup_ub_gu_se_274609 proquest_miscellaneous_2058508141 pubmed_primary_29932778 crossref_citationtrail_10_1080_0284186X_2018_1478124 crossref_primary_10_1080_0284186X_2018_1478124 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2018-11-02 |
PublicationDateYYYYMMDD | 2018-11-02 |
PublicationDate_xml | – month: 11 year: 2018 text: 2018-11-02 day: 02 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Acta oncologica |
PublicationTitleAlternate | Acta Oncol |
PublicationYear | 2018 |
References | CIT0010 CIT0001 CIT0011 StataCorp. (CIT0013) 2017 Shabo I (CIT0006) 2001; 98 National Quality Registry for Liver (CIT0002) 2016 Hu L (CIT0015) 2013; 16 John Neil P (CIT0012) 2017 CIT0014 Cancer Research UK (CIT0003) CIT0005 CIT0016 CIT0004 CIT0018 CIT0017 Hennedige TP (CIT0007) 2014; 14 CIT0009 CIT0008 CIT0019 |
References_xml | – ident: CIT0017 doi: 10.1093/oxfordjournals.annonc.a010676 – volume: 16 start-page: 631 year: 2013 ident: CIT0015 publication-title: J Breast Cancer – ident: CIT0016 doi: 10.1046/j.1440-1746.2001.02520.x – ident: CIT0018 doi: 10.1056/NEJMoa0908721 – ident: CIT0009 doi: 10.1111/hpb.12444 – ident: CIT0010 doi: 10.1080/00365521.2017.1284895 – ident: CIT0005 doi: 10.1634/theoncologist.2009-0302 – ident: CIT0014 doi: 10.1007/s12094-012-0988-7 – volume-title: Bile Duct and Gallbladder Cancer (SweLiv), Årsrapport nationellt kvalitetsregister year: 2016 ident: CIT0002 – ident: CIT0019 doi: 10.1186/s12885-015-1617-y – ident: CIT0004 doi: 10.1007/s11605-010-1335-3 – volume-title: Adjuvant capecitabine for biliary tract cancer: the BILCAP randomized study. Abstract 4006 ASCO year: 2017 ident: CIT0012 – ident: CIT0008 doi: 10.1002/jmri.24537 – volume: 98 start-page: 4584 year: 2001 ident: CIT0006 publication-title: La¨kartidningen – ident: CIT0011 doi: 10.1002/cncr.20160 – volume-title: Stata: release 15. Statistical software year: 2017 ident: CIT0013 – volume: 14 start-page: 14 year: 2014 ident: CIT0007 publication-title: Cancer Imaging doi: 10.1186/1470-7330-14-14 – ident: CIT0001 doi: 10.1155/2015/967472 – volume-title: Gallbladder cancer ident: CIT0003 |
SSID | ssj0002375 |
Score | 2.3226511 |
Snippet | Gallbladder cancer (GBC) has an extremely poor outcome. The aim of this study was to examine trends in GBC incidence, treatment and overall survival in a... Background: Gallbladder cancer (GBC) has an extremely poor outcome. The aim of this study was to examine trends in GBC incidence, treatment and overall... |
SourceID | swepub proquest pubmed crossref |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 1482 |
SubjectTerms | Aged Aged, 80 and over Cancer and Oncology Cancer och onkologi carcinoma Cholecystectomy - methods Female Gallbladder Neoplasms - epidemiology Gallbladder Neoplasms - mortality Gallbladder Neoplasms - pathology Gallbladder Neoplasms - therapy Humans Incidence Lymph Node Excision Male management Middle Aged Palliative Care Proportional Hazards Models Survival Analysis Sweden - epidemiology |
Title | Gallbladder cancer – no improvement in survival over time in a Swedish population |
URI | https://www.ncbi.nlm.nih.gov/pubmed/29932778 https://www.proquest.com/docview/2058508141 https://gup.ub.gu.se/publication/274609 |
Volume | 57 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELagKyEuiDflJSMhLlVWteM4ybEFlhVikRC7Um-R4zjLipJUaQISv54Z20nDUsTjklZO4qqer59nmplvCHmuUsallsh-CkW1mQnySOhgHumC56WRnGHt8Ml7eXwm3q6i1a7bpq0uafND_X1vXcn_WBXGwK5YJfsPlh0mhQF4D_aFI1gYjn9l4zdqvc7XyB0NZm9p23uuqrH0samtELhtALDtgA--otcJ39B2k8dRNfv4DYtyP802QxOvsau60K2a1ZX27Dhk7kAQX7nH641L8B3Se7G8YUgXay4-79it3Lb2kfxSWvi9q8d_NrDEVt05tjSOIGXEAnDZVmMGdRLTPVLYiA9RZXQvUfvMRtgcWSJXmGKXAGnH6G6Mr4f13nyx1oNtM-Sxa_dzSSG7P3WVHMAL5xNysFi-Wh4NOzIP46iv3kJd9X2fiqrQfp6fXZRf4o5LorLWETm9SW74CIIuHBxukSumuk2unfgciTvkwwgV1KGCBrSq6QgV9KKiPSooooIiKnBUUY8KukPFXXJ29Pr05XHgG2cEOkxFCxFTajgL8ySOi5IzXWijBed5XOQqkZrFTAvwjaTkZaTAf9SiRJX_JDZlUirFw3tkUtWVeUAoRDU6VKUpTGkExOapnqeJKJJSGgWhsJoS0a9Vpr2qPDY3WWesF5_1q53hamd-tafkcLht42RV_nTDs94QGRAgPtVSlam7LVwFES84toJNyX1noWHK3qJT8sKZbDiDqurn3SaDofMu25qMx0LO04e_neIRub77QTwmk7bpzBPwR9v8qYfbD9Z0hIg |
linkProvider | EBSCOhost |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Gallbladder+cancer+-+no+improvement+in+survival+over+time+in+a+Swedish+population&rft.jtitle=Acta+oncologica&rft.au=Lindn%C3%A9r%2C+Per&rft.au=Holmberg%2C+Erik&rft.au=Hafstr%C3%B6m%2C+Lo&rft.date=2018-11-02&rft.eissn=1651-226X&rft.volume=57&rft.issue=11&rft.spage=1482&rft_id=info:doi/10.1080%2F0284186X.2018.1478124&rft_id=info%3Apmid%2F29932778&rft.externalDocID=29932778 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0284-186X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0284-186X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0284-186X&client=summon |